Catholic University of the Sacred Heart, Rome, Italy.
J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11.
HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
HIV-1 耐药性是感染和疾病控制的主要障碍。本回顾性研究分析了欧洲 7 个国家接受抗逆转录病毒治疗（ART）的个体中耐药性的趋势和决定因素。在 20323 例病例中，80%至少携带一种耐药突变：从 1997 年的 81%降至 2008 年的 71%。预测广泛的 3 类耐药性很少见（考虑累积基因型为 3.2%），并在 2005 年达到 4.5%的峰值，此后逐渐下降。可用药物选择耗尽的病例比例从 2000 年的 32%降至 2008 年的 1%。多变量分析证实了耐药性随时间推移而降低的风险。
